+
-

Clinical Trials and Research

Change Text Size

Studies Currently Enrolling

Age-Related Macular Degeneration

Exudative ('Wet') Age-Related Macular Degeneration

Portal/Archway

Phase III Study evaluating extended delivery of intravitreal Lucentis using a refillable implant. Sponsored by Genentech

 

 

Emerge Study

Study evaluating intravitreal injection of hI-con1 as monotherapy or in combination with Lucentis as compared with Lucentis in patients with choroidal Neovascularization Secondary to ARMD. Sponsored by ICONIC

 

Sequoia Study

Study evaluating abicipar (an antiVEGF drug) as monotherapy compared with Lucentis for patients with choroidal neovascularization in AMD. Sponsored by Allergan

Non-Exudative ('Dry') Age-Related Macular Degeneration

 

 

Exposure Study

PHASE II Multi-center, randomized, sham injection-controlled exposure-response study of Lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy

 

Seattle

Emixustat for treatment of Geographic Atrophy. Sponsored by Acucela. NOTE THAT ENROLLMENT FOR THIS STUDY IS COMPLETED

Retinal Vein Occlusion

Ozurdex for RVO

Study evaluating Ozurdex implant for patients with macular edema due to RVO resistant to prior intravitreal injections of anti VEGF drugs. CLOSED TO FURTHER ENROLLMENT

Sponsored by Allergan.

Diabetic Macular Edema (DME)

Vista

Eylea for Diabetic Macular Edema. Sponsored by Regeneron. NOTE THAT ENROLLMENT FOR THIS IS COMPLETED.

 

Future Studies Involvement Scheduled. Enrollment dates Pending.

Genetic Study Investigations

Eyegene

Study evaluating genetics of retinal dystrophies and degenerations

Completed Studies

 

  • Collaborative Ocular Melanoma Study- Sponsored by National Eye Institute
  • Submacular Surgery Trial- Sponsored by National Eye Insititute
  • Complications of Age-Related Prevention Trial (CAPT)- Sponsored by National Eye Institute
  • Comparison of Age-Related Macular Degeneration Treatment Trial (CATT)- Sponsored by National Eye Institute
  • Diabetic Retinopathy Clinical Research Network (DCCR)
  • Intravitreal Triamcinolone vs. Grid Laser
  • Standard of Care vs Corticosteroid for Retinal Vein Occusion Study (SCORE)
  • High Dose Lucentis for the Treatment of Exudative Age-Related Macular Degeneration (Harbor Trial)- Sponsored by Genentech
  • Lucentis Treatment of Retinal Vein Occlusion (SHORE)- Sponsored by Genentech
  • Lucentis Treatment for Exudative Age-Related Macular Degeneration (Marina Trial)- Sponsored by Genentech
  • Age-Related Eye Disease Study II (AREDS II)
  • Lucentis for Branch Retinal Vein Occlusion (BRAVO)- Sponsored by Genentech
  • Lucentis for Central Retinal Vein Occlusion (CRUISE)- Sponsored by Genentech
  • Lucentis for Retinal Vein Occlusion (HORIZON)
  • Lucentis for AMD Patients Previously Enrolled in MARINA/FOCUS Trials (HORIZON)- Sponsored by Genentech
  • Lucentis for Age-Related Macular Degeneration (SAILOR)- Sponsored by Genentech
  • Lucentis vs. Visudyne Photodynamic Therapy (DENALI)
  • Phase i/II Study of Lucentis vs. Visudyne (FOCUS)
  • VIT-1000
  • Visudyne/Intravitreal Triamcinolone vs. Visudyne/Macugen for AMD (VERITAS)
  • Visydyne for Minimally Classic AMD (VMC)
  • ASPEN Study for Non-Insulin Dependant Diabetes
  • Transpupillary Thermotherapy for Choroidal Neovascularization (TTT4CNV)
  • Choroidal Neovascularization Prevention Trial Pilot Study (CNVPT)
  • Interferon for Age-Related Macular Degeneration
  • Radiation Treatment for ARMD
  • Microplasmin for Non-Surgical Treatment of Vitreomacular Traction Syndrome- Sponsored by Thrombogenics)
  • Lucentis for Diabetic Macular Edema (RISE)- Sponsored by Genentech
  • Chroma Study (Lampalizumab for dry Atrophic AMD
  • Fovista Study: Phase III Study evaluating Avastin or Eylea  in combination with Fovista (anti-Platelet Derived Growth Factor Drug) for the treatment of Choroidal neovascularization due to ARMD. Sponsored by Ophthotech